PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial

2024-09-13
(Press-News.org) Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

The investigational mRNA cancer immunotherapy is targeted for patients with lung cancer, melanoma and other solid tumours. Nineteen patients with advanced stage cancers received between one and nine doses of the immunotherapy treatment. Scientists have found the immunotherapy created an immune response against cancer and was well tolerated, with adverse events including fatigue, injection site pain and fever.

Results from the Phase I trial, also the first-in-human study of the therapy, are being presented on Saturday, 14th September at the European Society of Medical Oncology conference in Barcelona by the UK Chief Investigator of the trial from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust. The trial is sponsored by Moderna.

The mRNA immunotherapy is just one of many cancer vaccines entering clinical trials around the world. The therapy works by presenting common markers of tumours to patients’ immune systems, training them to recognise and fight cancer cells that express them and potentially eliminate cells that could supress the immune system.

The Phase I trial was designed to test the safety and tolerability of the immunotherapy, and secondary and tertiary objectives were to assess the radiographic and immunological responses.

Eight out of sixteen patients who could have their responses evaluated were able to demonstrate their tumour size did not grow and no new tumours appeared.

Data also showed the mRNA immunotherapy could activate the immune system in many patients, generating immune cells in the blood that could recognise the two proteins of interest (PD-L1 and IDO1). Researchers were able to show in some patients that the immunotherapy can increase levels of important immune cells that can kill cancer cells as well as reduced levels of other immune cells that can prevent the immune system from fighting cancer.

The results should be treated with caution, say the study authors, as the sample size was small and the primary objective of the study was to test for safety and determine the optimal dose of the immunotherapy. However, these promising early results support further research into mRNA-4359.

The trial continues to recruit patients with melanoma and lung cancer in combination with the immunotherapy drug pembrolizumab to provide more information on the safety and efficacy of the therapy.

The UK’s Chief Investigator of the trial Dr Debashis Sarker, a Clinical Reader in Experimental Oncology at King’s College London and a consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, said: “This study evaluating an mRNA cancer immunotherapy is an important first step in hopefully developing a new treatment for patients with advanced cancers.

“We have shown that the therapy is well tolerated without serious side effects and can stimulate the body’s immune system in a way that could help to treat cancer more effectively. However, as this study has only involved a small number of patients to date, it’s too early to say how effective this could be for people with advanced stage cancer.

“The trial continues to recruit patients with melanoma and lung cancers and is a huge international effort across the UK, USA, Spain and Australia.”

Kyle Holen, M.D., Moderna's Senior Vice President and Head of Development, Therapeutics and Oncology, said: "We are encouraged by the Phase 1 results of mRNA-4359, which demonstrate its potential to elicit strong antigen-specific T-cell responses while maintaining a manageable safety profile.

“This novel approach could be a key component in shifting the tumour microenvironment toward a more immune-permissive state, offering potential hope for patients with advanced solid tumours."

END


ELSE PRESS RELEASES FROM THIS DATE:

Rapid new blood diagnostic test for ALS

Rapid new blood diagnostic test for ALS
2024-09-13
(Jackson, Wyoming – Embargoed until Thursday 12 September 2024 8:00 PM EDT) A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that effects neurons in the brain and spinal cord.  ALS leads to gradual paralysis, ultimately resulting in the inability to walk, speak, or, in later stages, move. Currently, diagnosis is based on a thorough clinical examination, but it can take up to 12 months to provide a definitive diagnosis, by which time many patients have significantly ...

Ignore antifungal resistance in fungal disease at your peril, warn top scientists

2024-09-12
Without immediate action, humanity will potentially face further escalation in resistance in fungal disease, a renowned group of scientists from the across the world has warned. The commentary -  published in The Lancet this week - was coordinated by scientists at The University of Manchester, the Westerdijk Institute and the University of Amsterdam. According to the scientists most fungal pathogens identified by the World Health Organisation - accounting for around 3.8 million deaths a year - are either already resistant or rapidly acquiring resistance to antifungal drugs. The authors argue that the currently narrow focus on bacteria will not fully combat antimicrobial resistance ...

Increased testing for heart disease indicator needed worldwide

2024-09-12
Review in The Lancet finds that one in five globally are at risk of contracting cardiovascular diseases, because they carry a genetic risk of high levels of a specific lipoprotein, which can be tested for and possibly treated. 20 % of the world population carries a genetic risk factor for cardiovascular diseases such as heart attacks, strokes, and aortic valve stenosis: Increased levels of a lipid particle called lipoprotein(a). It is the most common genetic cause of cardiovascular diseases. “Lipoprotein(a) is the direct cause of cardiovascular diseases much like cigarettes cause ...

Huge gamma-ray burst collection 'rivals 250-year-old Messier catalogue'

Huge gamma-ray burst collection rivals 250-year-old Messier catalogue
2024-09-12
Huge gamma-ray burst collection 'rivals 250-year-old Messier catalogue' Royal Astronomical Society press release RAS PR 24/24 Embargoed until 00:01 BST on Friday 13 September 2024   Hundreds of gamma-ray bursts (GRBs) have been recorded as part of an enormous global effort so extensive it "rivals the catalogue of deep-sky objects created by Messier 250 years ago", astronomers say. GRBs are the most violent explosions in the Universe, releasing more energy than the Sun would in 10 billion years. They occur when either a massive star dies or two neutron stars merge. The explosions are so ...

Crude oil decimates sea otter buoyancy

2024-09-12
 Sea otters are famed for their luscious pelts, but the fur almost led to their extinction. By 1938, only a tiny population of ~50 remained clinging to the central California coast. Since then, the mammals have battled back; however, the charismatic creatures are still at risk from crude oil spilled by offshore rigs. But no one knew how severely crude oil impacts the buoyancy of sea otter fur or how well it recovers after cleaning. And Kate Riordan from California Polytechnic State University San Luis ...

Semaglutide and tirzepatide lead to better blood sugar control and weight loss in individuals with type 1 diabetes, US study finds

2024-09-12
Semaglutide and tirzepatide treatment lead to significant weight loss and improve blood sugar control in individuals with type 1 diabetes (T1D) who are living with overweight or obesity, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) has found. The two relatively new drugs are approved to treat type 2 diabetes and for weight loss. In type 2 diabetes, they help the body produce more insulin when needed. ...

Fear of hypoglycaemia remains a major barrier to exercise among adults with type 1 diabetes

2024-09-12
Despite high use of continuous glucose monitoring and insulin pump therapy, fear of hypoglycaemia (low blood sugar) remains a significant barrier to physical activity and exercise for adults with type 1 diabetes (T1D), according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). However, the findings suggest that if exercise and diabetes management are discussed in the clinic, this fear could be reduced. “Regular exercise can help individuals with diabetes to achieve their blood glucose goals, improve their ...

New technology ‘game changing’ for marathon runners with type 1 diabetes

2024-09-12
A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses informed by an insulin pump algorithm helped three adults with type 1 diabetes better manage their blood sugars enabling them to lead more active lives, and even run marathons. The AID system contains an advanced hybrid closed loop algorithm that automates the delivery of both basal and correction bolus insulin every 5 minutes based on sensor glucose values. “It is great to see advances in ...

Vitis vinifera and muscadines: Grape breeders seek the best of both grapes

Vitis vinifera and muscadines: Grape breeders seek the best of both grapes
2024-09-12
By John Lovett Arkansas Agricultural Experiment Station FAYETTEVILLE, Ark. — Muscadines may be the folksy American of the grape world, but they have many qualities like disease resistance and unique flavors that are desired in the more popular Vitis vinifera (bunch grapes) species. Likewise, Vitis vinifera — the species that most people eat as table grapes and drink in wine — has many characteristics desirable for muscadines, like thinner skin, a crispier texture and seedlessness. Successfully combining traits from these two species of grapes is a challenge due to differing numbers ...

A new tack for slack: motivate workers

2024-09-12
Workplace communications platforms such as Slack and Microsoft Teams are sometimes accused of reducing productivity by distracting workers with constant messages and the need to respond to them. But new research by Wen Wen, associate professor of information, risk, and operations management (IROM) at Texas McCombs, shows that companies can use them to do the opposite: to motivate workers. How? By praising successful employees in all-staff channels that everyone can see — especially when they can’t see one another face-to-face. “One important challenge faced by many companies is how to motivate remote workers and keep them productive,” ...

LAST 30 PRESS RELEASES:

Arthropods dominate plant litter decomposition in drylands

World-renowned organic chemists attend inaugural science symposium hosted by Rice’s Global Paris Center

The trees of Miami’s future

MIT team takes a major step toward fully 3D-printed active electronics

Accelerated three-year medical school students perform as well as peers in traditional four-year programs

SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa

Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival

Survivors of childhood brain cancer are more likely to be held back in school

Updating offshore turbine designs to reflect storms’ complexity is key

Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults

Scientists unveils key role of “selfish DNA” in early human development

Bonobos may be more vulnerable than previously thought, suggests genetics study

Scripps Research scientists discover chemical probes for previously “undruggable” cancer target

Giant Magellan telescope begins primary mirror support system testing

Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models

Political candidates who fight climate change stand to benefit in election

Stand up to Cancer announces new grants supporting pioneering research in six cancer types

Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia

New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen

JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year

ERC grant for groundbreaking wearable health tech

NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics

APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award

Election delays and voter trust

US air pollution monitoring network has gaps in coverage, say researchers

Continuous monitoring of fatigue in factory workers

Farmer ants’ wearable bacteria

Political polarization and trust

Study uncovers how silkworm moth's odor detection may improve robotics

New study links obesity to elevated hypertension risk among young middle eastern women

[Press-News.org] Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial